Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use
Ceftobiprole medocaril is a fifth-generation cephalosporin (anti-MRSA cephem) with a broad spectrum of antibacterial activity. Ceftobiprole is active against gram-positive bacteria, including strains resistant to other beta-lactams, such as methicillin-resistant Staphylococcus aureus and penicillin-...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2024-09-01
|
| Series: | Клиническая микробиология и антимикробная химиотерапия |
| Subjects: | |
| Online Access: | https://cmac-journal.ru/publication/2024/3/cmac-2024-t26-n3-p302/cmac-2024-t26-n3-p302.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841539812205527040 |
|---|---|
| author | Rachina S.A. Fedina L.V. Stafeev A.N. Kremneva A.O. Dekhnich A.V. |
| author_facet | Rachina S.A. Fedina L.V. Stafeev A.N. Kremneva A.O. Dekhnich A.V. |
| author_sort | Rachina S.A. |
| collection | DOAJ |
| description | Ceftobiprole medocaril is a fifth-generation cephalosporin (anti-MRSA cephem) with a broad spectrum of antibacterial activity. Ceftobiprole is active against gram-positive bacteria, including strains resistant to other beta-lactams, such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, as well as gram-negative bacteria such as Pseudomonas aeruginosa. The purpose of this review is to consider the mechanism of action and safety profile of ceftobiprole, as well as to summarize the results of clinical studies of the drug. Possible areas of clinical use of ceftobiprole for infections of the skin and soft tissues, complicated staphylococcal bacteremia, infective endocarditis, as well as communityacquired and nosocomial pneumonia are given. Summarizing the available information, ceftobiprole can be considered as the most important antibacterial drug for the treatment of severe pneumonia not associated with mechanical ventilation, skin and soft tissue infections, as well as a part of combination antimicrobial therapy for infective endocarditis. |
| format | Article |
| id | doaj-art-6e591dd5715c41fab6b64a2e298628ca |
| institution | Kabale University |
| issn | 1684-4386 2686-9586 |
| language | Russian |
| publishDate | 2024-09-01 |
| publisher | Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy |
| record_format | Article |
| series | Клиническая микробиология и антимикробная химиотерапия |
| spelling | doaj-art-6e591dd5715c41fab6b64a2e298628ca2025-01-14T06:34:30ZrusInterregional Association for Clinical Microbiology and Antimicrobial ChemotherapyКлиническая микробиология и антимикробная химиотерапия1684-43862686-95862024-09-0126330231010.36488/cmac.2024.3.302-310cmac-2024-t26-n3-p302Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical useRachina S.A.0Fedina L.V.1Stafeev A.N.2Kremneva A.O.3Dekhnich A.V.4I.M. Sechenov First Moscow State Medical University, Moscow, RussiaCity Clinical Hospital named after S.S. Yudin, Moscow, RussiaI.M. Sechenov First Moscow State Medical University, Moscow, RussiaI.M. Sechenov First Moscow State Medical University, Moscow, RussiaInstitute of Antimicrobial Chemotherapy, Smolensk, RussiaCeftobiprole medocaril is a fifth-generation cephalosporin (anti-MRSA cephem) with a broad spectrum of antibacterial activity. Ceftobiprole is active against gram-positive bacteria, including strains resistant to other beta-lactams, such as methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, as well as gram-negative bacteria such as Pseudomonas aeruginosa. The purpose of this review is to consider the mechanism of action and safety profile of ceftobiprole, as well as to summarize the results of clinical studies of the drug. Possible areas of clinical use of ceftobiprole for infections of the skin and soft tissues, complicated staphylococcal bacteremia, infective endocarditis, as well as communityacquired and nosocomial pneumonia are given. Summarizing the available information, ceftobiprole can be considered as the most important antibacterial drug for the treatment of severe pneumonia not associated with mechanical ventilation, skin and soft tissue infections, as well as a part of combination antimicrobial therapy for infective endocarditis.https://cmac-journal.ru/publication/2024/3/cmac-2024-t26-n3-p302/cmac-2024-t26-n3-p302.pdfceftobiprole medocarilpneumoniaendocarditismethicillinresistant staphylococcus aureuspseudomonas aeruginosa |
| spellingShingle | Rachina S.A. Fedina L.V. Stafeev A.N. Kremneva A.O. Dekhnich A.V. Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use Клиническая микробиология и антимикробная химиотерапия ceftobiprole medocaril pneumonia endocarditis methicillinresistant staphylococcus aureus pseudomonas aeruginosa |
| title | Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use |
| title_full | Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use |
| title_fullStr | Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use |
| title_full_unstemmed | Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use |
| title_short | Ceftobiprole medocaril: clinical and pharmacological characteristics and possibilities of clinical use |
| title_sort | ceftobiprole medocaril clinical and pharmacological characteristics and possibilities of clinical use |
| topic | ceftobiprole medocaril pneumonia endocarditis methicillinresistant staphylococcus aureus pseudomonas aeruginosa |
| url | https://cmac-journal.ru/publication/2024/3/cmac-2024-t26-n3-p302/cmac-2024-t26-n3-p302.pdf |
| work_keys_str_mv | AT rachinasa ceftobiprolemedocarilclinicalandpharmacologicalcharacteristicsandpossibilitiesofclinicaluse AT fedinalv ceftobiprolemedocarilclinicalandpharmacologicalcharacteristicsandpossibilitiesofclinicaluse AT stafeevan ceftobiprolemedocarilclinicalandpharmacologicalcharacteristicsandpossibilitiesofclinicaluse AT kremnevaao ceftobiprolemedocarilclinicalandpharmacologicalcharacteristicsandpossibilitiesofclinicaluse AT dekhnichav ceftobiprolemedocarilclinicalandpharmacologicalcharacteristicsandpossibilitiesofclinicaluse |